# AevisBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aevisbio

- Industry: Biotechnology
- Headquarters: Daejeon, South Korea
- Website: www.aevisbio.com
- Total disclosed funding: $8.6M
- Latest round: Series A (Sep 6, 2021)
- Investors on record: 3

## About

Based in Daejeon, South Korea, and founded in 2018, AevisBio provides a scientific solution for drug development targeting incurable diseases such as inflammatory diseases, neurological disorders, and drug-resistant cancers. The company is building a portfolio of proteolytic drugs based on a novel immunomodulatory amide or IMiD low-molecular compound. Based on IMiD materials, AevisBio is conducting preclinical development targeting degenerative brain diseases such as traumatic brain injury or TBI and licensed the exclusive right to IMiD pomalidomide derivative-related pharmaceutical technology for use as a TPD precursor from the US National Institutes of Health in January 2021.

The company develops and manufactures PROTAC, a bivalent proteolytic anticancer drug treatment of intractable diseases based on an immunomodulatory molecule (IMiD) compound.

AevisBio plans to expand its indications to inflammatory diseases based on the inflammation-regulating action of IMiD.

## Funding rounds

- Series A, Sep 6, 2021, $8.6M — KB Investment, Timefolio Asset Management, We Venture Partners

## Investors

- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series A
- Timefolio Asset Management — Series A
- We Venture Partners (https://capitalatlas.ai/funds/we-venture-partners) — Series A